SillaJen Applies for Change in Pexa-Vec Phase 1b/2a Clinical Trial Plan
[Asia Economy Reporter Minwoo Lee] On the 10th, SillaJen announced that it has applied for a dose escalation and safety/efficacy evaluation of Pexa-Vec combined with Semiplimab (REGN2810, anti-PD-1) in subjects with metastatic or unresectable renal cell carcinoma (RCC, kidney cancer), as well as a change in the Phase 1b/2a clinical trial plan.
Hot Picks Today
!["Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]](https://cwcontent.asiae.co.kr/asiaresize/93/2025061015355092669_1749537351.jpg)
"Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- "Can't Even Turn On a Fan? How Will They Endure the Heat?"... Massive Blackout Hits the Philippines Amid Scorching Heat
- "Drink Three Cups of Coffee and Stay Up All Night Before the Test"... Manual of Insurance Planner Who Collected 1 Billion Won in Payouts
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]
The company explained, "Through this clinical trial, we will evaluate the safety, antitumor activity, and efficacy of Pexa-Vec combined with Semiplimab in subjects with renal cell carcinoma."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
